1. P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes. (April 2023) Authors: Johnston, S.; Toi, M.; O'Shaughnessy, J.; Rastogi, P.; Campone, M.; Neven, P.; Huang, C.S.; Huober, J.; Jaliffe, G. Garnica; Cicin, I.; Tolaney, S.; Goetz, M.P.; Rugo, H.; Senkus, E.; Testa, L.; Del Mastro, L.; Shimizu, C.; Wei, R.; Shahir, A.; Munoz, M. Journal: Breast Issue: Volume 68(2023) Page Start: S22 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗